Fractyl Health (NASDAQ:GUTS) Given New $4.00 Price Target at Morgan Stanley

Fractyl Health (NASDAQ:GUTS) had its price target reduced by Morgan Stanley to $4.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley‘s price target would indicate a potential upside of 200.75% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Craig Hallum set a $5.00 target price on shares of Fractyl Health in a research report on Monday. Finally, Weiss Ratings downgraded shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $50.25.

Fractyl Health Stock Down 3.6%

GUTS traded down $0.05 on Monday, hitting $1.33. The company had a trading volume of 465,235 shares, compared to its average volume of 331,362. The stock has a fifty day moving average price of $6.61 and a 200-day moving average price of $8.00. Fractyl Health has a 12-month low of $1.33 and a 12-month high of $29.34. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The stock has a market capitalization of $17.64 million, a price-to-earnings ratio of -0.13 and a beta of 2.42.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.44) EPS for the quarter, beating the consensus estimate of ($1.62) by $0.18. Analysts predict that Fractyl Health will post -6.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC acquired a new stake in Fractyl Health in the second quarter worth about $8,968,058. Bank of America Corp DE purchased a new stake in shares of Fractyl Health during the second quarter worth about $4,791,000. General Catalyst Group Management LLC acquired a new position in shares of Fractyl Health during the second quarter valued at about $3,880,000. Pale Fire Capital SE increased its holdings in shares of Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares in the last quarter. Finally, BlackRock Inc. purchased a new position in shares of Fractyl Health in the 2nd quarter valued at approximately $1,431,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.